ABCL
AbCellera Biologics Inc.
$9.34
+2.41
(+34.78%)
Mkt Cap
2.84B
Volume
45,715,210
52W Range
2.745-9.75
Sector
Healthcare
Beta
1.19
EPS (TTM)
-0.54 USD
P/E Ratio
-6.98
Revenue (TTM)
66.17M USD
Rev Growth (5Y)
-20.3%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$9.41
Fair Value
weak signal
1.1% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 75.13M | 28.83M | 38.02M | 485.42M | 375.20M | 233.16M | 11.61M | 8.83M |
| Net Income | (146.41M) | (162.86M) | (146.40M) | 158.52M | 153.46M | 118.92M | (2.21M) | 309,000 |
| EPS | -0.49 | -0.55 | -0.51 | 0.56 | 0.56 | 0.32 | -0.01 | 0.00 |
| Free Cash Flow | (174.07M) | (186.95M) | (121.38M) | 204.70M | 186.13M | 8.02M | (1.30M) | (1.74M) |
| FCF / Share | -0.58 | -0.64 | -0.42 | 0.72 | 0.67 | 0.03 | -0.01 | -0.01 |
| Operating CF | (131.29M) | (108.56M) | (43.88M) | 277.36M | 244.58M | 22.69M | 2.69M | 3.56M |
| Total Assets | 1.36B | 1.36B | 1.49B | 1.54B | 1.32B | 1.01B | 23.49M | 21.49M |
| Total Debt | 143.22M | 65.36M | 77.38M | 82.26M | 40.06M | 6.78M | 6.89M | 3.44M |
| Cash & Equiv | 128.51M | 156.32M | 133.32M | 386.54M | 476.14M | 594.12M | 7.55M | 10.44M |
| Book Value | 966.90M | 1.06B | 1.15B | 1.23B | 1.03B | 830.51M | 10.25M | 11.61M |
| Return on Equity | -0.15 | -0.15 | -0.13 | 0.13 | 0.15 | 0.14 | -0.22 | 0.03 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.05M | 8.31M | 44.85M | 8.96M | 17.08M | 4.24M | 5.05M | 6.51M | 7.32M | 9.95M | 9.18M | 6.60M |
| Net Income | (55.43M) | (43.16M) | (8.95M) | (57.12M) | (34.73M) | (45.62M) | (34.21M) | (51.11M) | (36.93M) | (40.61M) | (47.15M) | (28.61M) |
| EPS | -0.18 | -0.14 | -0.03 | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.16 | -0.10 |
| Free Cash Flow | (35.99M) | (37.35M) | (44.59M) | (61.52M) | (45.77M) | (22.19M) | (23.63M) | (47.58M) | (49.26M) | (65.85M) | (34.04M) | (20.44M) |
| FCF / Share | -0.12 | -0.12 | -0.15 | -0.21 | -0.15 | -0.07 | -0.08 | -0.16 | -0.17 | -0.22 | -0.12 | -0.07 |
| Operating CF | (33.86M) | (33.52M) | (34.74M) | (52.59M) | (32.40M) | (11.55M) | (8.00M) | (29.00M) | (29.46M) | (41.71M) | (19.61M) | (106,000) |
| Total Assets | 1.31B | 1.31B | 1.36B | 1.36B | 1.40B | 1.34B | 1.36B | 1.39B | 1.41B | 1.46B | 1.49B | 1.51B |
| Total Debt | 135.62M | 140.18M | 143.22M | 142.22M | 142.08M | 67.85M | 65.36M | 71.40M | 72.05M | 73.61M | 77.38M | 80.76M |
| Cash & Equiv | 120.06M | 77.06M | 128.51M | 83.16M | 92.44M | 159.27M | 156.32M | 126.64M | 148.31M | 123.57M | 133.32M | 172.42M |
| Book Value | 896.02M | 938.08M | 966.90M | 964.04M | 1.01B | 1.02B | 1.06B | 1.08B | 1.11B | 1.13B | 1.15B | 1.18B |
| Return on Equity | -0.06 | -0.05 | -0.01 | -0.06 | -0.03 | -0.04 | -0.03 | -0.05 | -0.03 | -0.04 | -0.04 | -0.02 |
ABCL News
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
AbCellera Biologics Inc. (ABCL) Q2 2026 Earnings Call Transcript
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates
AbCellera Biologics Q2 Earnings Call Highlights
AbCellera Reports Q2 2026 Business Results
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
Playing The Biotech Breakout With Insiders
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choice